April 25 (Reuters) - Cytokinetics Inc said its experimental treatment for Lou Gehrig's disease - a progressive neurodegenerative disorder - failed the main goal in a mid-stage trial.

The study tested the efficacy of the drug, tirasemtiv - one of the company's lead compounds - against a placebo in 711 patients with amyotrophic lateral sclerosis (ALS).

The San Francisco-based company's stock was halted before the bell on Friday.

(Reporting by Natalie Grover in Bangalore; Editing by Maju Samuel)